Ailleen Heras Herzig, MD
Endocrinology, Diabetes & Metabolism · Covington, KYNPI 1962545525
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 292 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 16.4% — the pattern of someone who eats at a lot of different presentations.
Across 292 payments — averaging $17.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$821
- Medtronic$810
- Amgen$525
- Lilly USA, LLC$472
- Corcept Therapeutics$354
- Novo Nordisk$343
- plus $2K from 31 others
What the payments were for
- Food & beverage$4,994100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 30 | $821 |
| Medtronic(2 entities) | 58 | $810 |
| Amgen(2 entities) | 26 | $525 |
| Lilly USA, LLC | 32 | $472 |
| Corcept Therapeutics | 20 | $354 |
| Novo Nordisk | 23 | $343 |
| Abbott | 14 | $216 |
| Boehringer Ingelheim | 11 | $177 |
| Sanofi-aventis U.S. LLC | 10 | $163 |
| Pfizer | 9 | $136 |
| AstraZeneca | 7 | $122 |
| AbbVie | 7 | $100 |
| Xeris Pharmaceuticals, Inc. | 4 | $64 |
| Amarin Pharma, Inc. | 3 | $63 |
| Neurocrine Biosciences, Inc. | 2 | $62 |
| Amryt Pharma Holdings Ltd | 3 | $52 |
| Esperion Therapeutics, Inc. | 3 | $49 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $47 |
| Lifescan, Inc. | 3 | $45 |
| Johnson & Johnson | 3 | $37 |
| Astellas Pharma US Inc | 2 | $36 |
| Eisai Inc. | 2 | $32 |
| BD | 1 | $29 |
| Sequel Med Tech, LLC | 1 | $27 |
| Bayer | 2 | $27 |
| Novartis | 1 | $26 |
| Tandem Diabetes Care, Inc. | 1 | $24 |
| Clarus Therapeutics Inc. | 2 | $21 |
| Ascendis Pharma Endocrinology Inc | 1 | $17 |
| Verity Pharmaceuticals Inc. | 1 | $15 |
| Insulet Corporation | 1 | $15 |
| Tolmar, Inc. | 1 | $14 |
| Zealand Pharma US, Inc. | 1 | $14 |
| Antares Pharma, Inc. | 1 | $13 |
| Regeneron Healthcare Solutions, Inc. | 1 | $13 |
| Merck | 1 | $13 |
| IBSA Pharma Inc. | 1 | $13 |
How this compares
$5,006 in reported general payments places this provider in the 60th percentile of 90 endocrinology, diabetes & metabolism providers in Kentucky.
See all endocrinology, diabetes & metabolism providers in Kentucky →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 258 | $342,862 |
| MounjaroTirzepatide | 184 | $228,732 |
| JardianceEmpagliflozin | 167 | $222,772 |
| FarxigaDapagliflozin Propanediol | 117 | $119,330 |
| ForteoTeriparatide | 25 | $112,994 |
| TrulicityDulaglutide | 67 | $112,755 |
| Tresiba Flextouch U-200Insulin Degludec | 32 | $64,812 |
| Repatha SureclickEvolocumab | 61 | $54,566 |
| TymlosAbaloparatide | 17 | $46,582 |
| GlyxambiEmpagliflozin/Linagliptin | 54 | $43,335 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 207 | $36,770 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 52 | $36,049 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 33 | $35,939 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $34,240 |
| Tresiba Flextouch U-100Insulin Degludec | 28 | $32,789 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Forteo, Trulicity | $472 | $454,481276 claims |
| Novo NordiskOzempic | $343 | $342,862258 claims |
| Boehringer IngelheimJardiance, Glyxambi, Tradjenta | $177 | $297,366251 claims |
| AstraZenecaFarxiga | $122 | $119,330117 claims |
| MerckJanumet Xr, Januvia | $13 | $67,83454 claims |
| Johnson & JohnsonInvokana | $37 | $13,03911 claims |
| AbbVieSynthroid | $100 | $6,434102 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 90 endocrinology, diabetes & metabolism providers in Kentucky.
Other endocrinology, diabetes & metabolism in Covington
- Yancey HolmesCovington$148K
- Wael EidCovington$31K
- Linda HermillerCovington$12K
- Jaspreet ChahalCovington$11K
- Irina KorablevaCovington$4K
- Bradley EilermanFlorence$1.3M
- Sergio Chang FigueroaMadisonville$1.2M
- Hisham AlrefaiLouisville$720K
- Harold BaysLouisville$214K
- Jahangir CyrusLouisville$155K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.